Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Optimi Health Corp (OP: OPTHF )

0.2437 -0.0023 (-0.93%)
Streaming Delayed Price Updated: 12:17 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,801
Open 0.2462
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2460
Today's Range 0.2437 - 0.2660
52wk Range 0.1100 - 0.4300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga

Performance

YTD
+4.59%
+4.59%
1 Month
+37.68%
+37.68%
3 Month
-3.60%
-3.60%
6 Month
+93.11%
+93.11%
1 Year
+37.76%
+37.76%

More News

Read More
Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute
Via Benzinga
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Via Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Via Benzinga
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
Via Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Via Benzinga
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Optimi Health Will Supply Psychedelics To Canada's SAP, Secures CA$1M Private Financing
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Via Benzinga
Natural Psilocybin Companies Diversify: Latest By Optimi, Red Light Holland And A European Player
Via Benzinga
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Via Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Via Benzinga
The Psychedelic Mushrooms Market; Between Legitimate Harvesting And Illegal Retail Sales
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Via Benzinga
Optimi Health Boosts Psilocybin Production With New Health Canada License And Supply Deal
Via Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Via Benzinga
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
Via Benzinga
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
Via Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Via Benzinga
How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out
Via Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.